Folic acid use by women with epilepsy: Findings of the Epilepsy Birth Control Registry

• Published in: Epilepsy & behavior 2017-07, Vol.72, p.156-160
• Main Authors: Herzog, Andrew G, MacEachern, Devon B, Mandle, Hannah B, Cahill, Kaitlyn E, Fowler, Kristen M, Davis, Anne R, Allen Hauser, W
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Anticonvulsants - therapeutic use; Contraception; Contraception - methods; Contraception - trends; Contraceptive Agents - therapeutic use; Dietary Supplements; Epidemiology; Epilepsy; Epilepsy - drug therapy; Epilepsy - epidemiology; Female; Folic acid; Folic Acid - therapeutic use; Humans; Middle Aged; Neurology; Pregnancy; Pregnancy Complications - drug therapy; Pregnancy Complications - epidemiology; Registries; Retrospective Studies; Seizures; Surveys and Questionnaires; Women; Young Adult
• ISSN: 1525-5050; 1525-5069
• DOI: 10.1016/j.yebeh.2017.05.007

Abstract Purpose To determine the prevalence and predictors of folic acid (FA) use by women with epilepsy (WWE) at risk of unintended pregnancy. Methods These retrospective data come from the Epilepsy Birth Control Registry (EBCR) web-based survey of 1144 WWE in the community, 18–47 years, who provided demographic, epilepsy, AED, contraception, pregnancy, healthcare visits and FA data. We report prevalence and predictors of FA use in relation to risk of pregnancy (not at risk, at risk, seeking pregnancy, pregnant), demographics, seizure types and AED and contraception categories. Results 368 (47.6%) of the 773 WWE at risk of unintended pregnancy in the EBCR took FA supplement. Being at risk was a significant predictor in comparison to WWE not at risk (OR = 1.464 [1.103–1.944], p = 0.008). In comparison to WWE at risk, FA use trended greater for WWE actively seeking pregnancy (29/47, 61.7% v 368/773, 47.6%; p = 0.0605) and was greater for pregnant WWE (17/19, 89.5% v 368/773, 47.6%; p = 0.0007). Demographic predictors for WWE at risk were race (p = 0.003), education (p = 0.012) and income (0.043) with significantly greater FA use by Caucasians than minorities and direct correlations between FA use and levels of education and household income. Seizure type, AED use, category and dosage, polytherapy and contraceptive category were not predictors. A healthcare provider visit during the year prior to the survey was not a predictor. Prevalence of FA use was similar following visits with gynecologists - 51.7%, neurologists – 48.7% and primary care – 48.6%. FA supplementation by prescription was greater for WWE at risk on AED versus no AED (190/355, 53.5% v 3/13, 23.1%; p = 0.045). Conclusion Low prevalence of preconception FA use may reflect a need for more education. In addition, further research is needed to provide definitive evidence that FA reduces congenital malformations in the offspring of WWE.